Ruxolitinib 1.5% cream, a topical Janus Kinase (JAK) 1/2 inhibitor, represents a novel targeted treatment for non-segmental vitiligo, a common acquired depigmentation disorder of autoimmune origin clinically characterized by milky-white patches on the affected body areas. The efficacy of topical ruxolitinib in vitiligo has been demonstrated in clinical trials and real-life observation, with an overall safety profile. Mild-to-moderate reported adverse events include site-application acne, nasopha